Core Insights - Recursion Pharmaceuticals (RXRX) reported a narrower loss of 21 cents per share in Q4 2025, compared to a loss of 53 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 28 cents [1][7] - The company achieved total revenues of $35.5 million in Q4 2025, significantly higher than the Zacks Consensus Estimate of $26 million, primarily due to a $30 million milestone payment from Roche and increased contributions from Sanofi [2][7] - For the full year 2025, Recursion recorded total revenues of $74.7 million, a 27% increase year over year, and a loss per share of $1.44, which was narrower than the loss of $1.69 per share in 2024 [8] Financial Performance - Research and development (R&D) expenses decreased by 2% to $95.9 million in Q4 2025, attributed to improved operational efficiency and a strategic reprioritization of the clinical portfolio [4] - General and administrative (G&A) expenses were reported at $33.7 million, down 56% year over year, mainly due to the absence of transaction expenses from the previous year's business combination with Exscientia [5] - The company ended 2025 with cash, cash equivalents, and restricted cash totaling $753.9 million, an increase from $667.1 million as of September 30, 2025, which is expected to fund operations into early 2028 [6] Pipeline Developments - Recursion has shifted focus to developing candidates in its clinical pipeline, including REC-4881 for familial adenomatous polyposis, which has shown promising preliminary data [9] - The company initiated a phase I/II DAHLIA study for REC-1245, targeting biomarker-enriched solid tumors and lymphoma, with data readout expected in the first half of 2026 [10] - REC102, a new candidate for treating hypophosphatasia, is anticipated to enter phase I studies by late 2026 following the acquisition of Rallybio's stake in their joint venture [12]

Financial Data and Key Metrics Changes - Total revenue for the second quarter was $264.6 million, representing a 9% year-over-year increase [6][28] - Debut net product sales were $96.1 million, up 14% year-over-year, with a 12% increase in volume [28] - NUPLAZID net product sales were $168.5 million, up 7% year-over-year, with 5% of that growth attributable to volume [29] - R&D expenses increased to $78 million from $76.2 million year-over-year, while SG&A expenses rose to $133.5 million from $117.1 million [29] - Cash balance at the end of the quarter was $762 million, up from $681.6 million at the end of Q1 [30] Business Line Data and Key Metrics Changes - Dayview sales were $96.1 million, with 987 unique patients receiving paid shipments, an increase from 954 in Q1 [9][10] - NUPLAZID saw a 17% year-over-year increase in referrals, with the highest number of new Puzzet bottles shipped since launch [16][17] Market Data and Key Metrics Changes - The proportion of new referrals from non-Center of Excellence (COE) accounts grew to about 75% of overall referrals, up from two-thirds the previous quarter [43] - The number of healthcare providers writing prescriptions for Debut increased to 900, with a significant portion coming from community settings [12][43] Company Strategy and Development Direction - The company is focused on accelerating the commercial trajectory of Debut and sustaining long-term growth for NUPLAZID [32] - Plans to initiate seven Phase II or Phase III studies over 2025 and 2026, with five data readouts expected between 2025 and 2027 [20][21] - The company aims to expand globally and reach more patients in need, with a strong emphasis on community engagement and patient support [7][32] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's performance and raised the low end of NUPLAZID's revenue guidance for the year to between $665 million and $690 million [30] - The company anticipates sustained growth through the second half of the year, driven by strong execution and ongoing direct-to-consumer campaigns [16][17] Other Important Information - The company hosted its first R&D Day, showcasing nine programs in development and highlighting the potential of new molecules [8][19] - Management noted recent litigation wins that enforce intellectual property for Neuclazid, reinforcing long-term strategy [7] Q&A Session Summary Question: Can you provide details on ACP101's top-line approach and key risks? - Management indicated that the focus will be on the primary endpoint and key safety and tolerability overview in the top-line announcement, with ongoing monitoring of trial conduct [34][35] Question: What percentage of new patients for Debut came from community settings? - Approximately 75% of referrals came from non-COE accounts, indicating successful penetration into the community [43] Question: How is the growth trajectory for Debut expected to evolve? - The company expects continued acceleration in new patient starts, supported by the new customer model and a stable base of persistent patients [49] Question: What are the key drivers for NUPLAZID's growth? - Growth is driven by increased referrals and ongoing direct-to-consumer campaigns, with strong performance across all channels [68] Question: What is the outlook for 2026 regarding growth for both brands? - The company anticipates continued growth for both Debut and NUPLAZID, leveraging recent momentum and expanding market opportunities [100][102]